Source: Business Wire

Press Release: Seikagaku Corporation : Ferring Presents Early Response Data From Pivotal Phase 3 Trial for Investigational Treatment, SI-6603 (condoliase), in Lumbar Disc Herniation at ASPN 2024

PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring presents early response data from pivotal Phase 3 trial for SI-6603 (condoliase) at ASPN 2024

Read full article »
Seikagaku Corporation's Competitors | Seikagaku Corporation's News | Seikagaku Corporation's Financials
Stay up-to-date with the latest news on Seikagaku Corporation
Annual Revenue
$100-500M
Employees
500-1.0K
Ken Mizutani's photo - President & CEO of Seikagaku Corporation

President & CEO

Ken Mizutani

CEO Approval Rating

- -/100

Read more
Stay up-to-date with the latest news on Seikagaku Corporation